Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

37.59
+0.14000.37%
Post-market: 37.590.00000.00%19:30 EDT
Volume:429.25K
Turnover:16.16M
Market Cap:3.62B
PE:-19.22
High:38.27
Open:37.74
Low:37.24
Close:37.45
52wk High:42.68
52wk Low:24.24
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.75
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.02
PE(LYR):-29.25

Loading ...

Ideaya Biosciences Teams With Roche to Test Combination Therapy in Pancreatic Cancer

MT Newswires Live
·
Jun 03

Ideaya Biosciences announces IDE892 collaboration with Roche

TIPRANKS
·
Jun 03

IDEAYA Biosciences, Roche collaborate on IDE892-RG6505 combo study in MTAP-deleted RAS-mutant pancreatic cancer

Reuters
·
Jun 03

IDEAYA Biosciences Announces Clinical Collaboration With Roche in Mtap-Deleted Ras-Mutant Pancreatic Cancer

THOMSON REUTERS
·
Jun 03

IDEAYA Biosciences - Co and Roche Retain All Commercial Rights to Their Respective Compounds

THOMSON REUTERS
·
Jun 03

IDEAYA Biosciences - to Sponsor Clinical Trial With Joint Governance With Roche

THOMSON REUTERS
·
Jun 03

IDEAYA Biosciences - to Initiate Phase 1 Combination Cohorts in Pdac and Nsclc

THOMSON REUTERS
·
Jun 03

IDEAYA Biosciences Price Target Maintained With a $58.00/Share by Wedbush

Dow Jones
·
Jun 02

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)

TIPRANKS
·
Jun 02

IDEAYA darovasertib-crizotinib combo cuts progression risk in Phase 2/3 OptimUM-02 metastatic uveal melanoma trial

Reuters
·
Jun 01

IDEAYA Biosciences and Servier Provide Complete Data From Phase 2/3 Registrational Optimum-02 Trial of the Darovasertib Combination in First Line Hla*a2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at Asco

THOMSON REUTERS
·
Jun 01

IDEAYA Biosciences grants 221,000 inducement stock options at USD 29.34 per share

Reuters
·
May 29

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 29

IDEAYA Biosciences to present at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 26

IDEAYA Biosciences (IDYA) Receives a Buy from LifeSci Capital

TIPRANKS
·
May 10

Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates

Simply Wall St.
·
May 07

RBC Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

TIPRANKS
·
May 06

IDEAYA Biosciences Files New Shelf Registration Statement

TIPRANKS
·
May 06

BRIEF-Ideaya Biosciences Inc - Enters Sales Agreement With Jefferies For Common Stock Offering Up To $350 Million - SEC Filing

Reuters
·
May 06

BRIEF-Ideaya Biosciences Inc Files For Mixed Shelf Offering, Size Not Disclosed- SEC Filing

Reuters
·
May 06